AxoGen, Inc. (NASDAQ:AXGN) Q3 2019 Earnings Conference Call - Final Transcript
Nov 06, 2019 • 04:30 pm ET
we are factoring it in as a modest contributor for next year.
Okay, fair enough. Thank you.
Peter J. Mariani
The next question is from David Turkaly of JMP Securities. Please go ahead.
Yeah, hi, this is actually Dan on for Dave, thanks for taking the question.
Peter J. Mariani
Hey. First off, just on the contribution to sales growth, in the second quarter, you mentioned mid single digit net price increase, can you just give us an idea of what this effect was in this quarter or rather, how the growth compared directionally to 2Q? Thanks.
It was about the same. So still mid-single digits.
Okay, great. And then just one quick follow-up, as far as sales force attrition, you mentioned last quarter that you expect it to be in a typical 10% to 15% annual rate. Has this changed at all? And then, any color on -- at what point you see the most attrition in terms of number of months n board for a rep? Thanks.
So no, we haven't seen any change in attrition. We expect this year to continue to be in that same sort of range. Second question months of attrition? I don't know that we see any particular pattern on that. So I don't have any color on that.
Okay, all right. Thanks a lot.
We have reached the end of the question-and-answer session. And I will now turn the call back over to Karen Zaderej, Chairman, CEO and President.
Thank you, Sachi. Well, I want to thank everyone for joining us on today's call and we look forward to seeing many of you at the Jefferies London Healthcare Conference later this month, and at the 31st Annual Piper Jaffray Healthcare Conference on December 5th in New York City. Thank you.
[Operator Closing Remarks].